Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

2O8Z

Bound Structure of CRF1 Extracellular Domain Antagonist

Summary for 2O8Z
Entry DOI10.2210/pdb2o8z/pdb
DescriptorcCRF(30-41) Peptide (1 entity in total)
Functional Keywordshelical, crf, peptide ligand, gpcr, ecd, extracellular domain, neuropeptide
Total number of polymer chains1
Total formula weight1509.84
Authors
Mesleh, M.F.,Shirley, W.A.,Heise, C.E.,Ling, N.,Maki, R.A.,Laura, R.P. (deposition date: 2006-12-12, release date: 2006-12-26, Last modification date: 2024-11-13)
Primary citationMesleh, M.F.,Shirley, W.A.,Heise, C.E.,Ling, N.,Maki, R.A.,Laura, R.P.
NMR structural characterization of a minimal peptide antagonist bound to the extracellular domain of the corticotropin-releasing factor1 receptor.
J.Biol.Chem., 282:6338-6346, 2007
Cited by
PubMed Abstract: Natural peptide agonists of corticotrophin-releasing factor (CRF) receptors bind to the receptor by a two-site mechanism as follows: the carboxyl end of the ligand binds the N-terminal extracellular domain (ECD) of the receptor and the amino portion of the ligand binds the extracellular face of the seven transmembrane region. Recently, peptide antagonists homologous to the 12 C-terminal residues of CRF have been derived, which bind the CRF(1) receptor through an interaction with the ECD. Here we characterized the binding of a minimal 12-residue peptide antagonist while bound to the isolated ECD of the CRF(1) receptor. We have expressed and purified soluble and properly folded ECD independent from the seven-transmembrane region as a thioredoxin fusion protein in Escherichia coli. A model of the peptide antagonist, cyclic corticotrophin-releasing factor residues 30-41 (cCRF(30-41)), was calculated while bound to the recombinant ECD using transferred nuclear Overhauser effect spectroscopy. Although the peptide is unstructured in solution, it adopts an alpha-helical conformation when bound to the ECD. Residues of cCRF(30-41) comprising the binding interface with the ECD were mapped using saturation transfer difference NMR. Two hydrophobic residues (Met(38) and Ile(41)) as well as two amide groups (Asn(34) and the C-terminal amide) on one face of the helix defined the binding epitope of the antagonist. This epitope may be used as a starting point for development of non-peptide antagonists targeting the ECD of this receptor.
PubMed: 17192263
DOI: 10.1074/jbc.M609816200
PDB entries with the same primary citation
Experimental method
SOLUTION NMR
Structure validation

247536

PDB entries from 2026-01-14

PDB statisticsPDBj update infoContact PDBjnumon